劲方医药:GFH375治疗肺癌III期临床正式启动 首例患者入组

财中社
Aug 10

8月10日,劲方医药(02595)发布公告,口服KRAS G12D抑制剂GFH375针对非小细胞肺癌的注册性III期“麒麟飞01”研究正式启动,全国超40家中心参与,南京鼓楼医院完成首例患者入组。  该药物此前已启动胰腺癌III期“麒麟翼01”研究,并拿下NSCLC、胰腺癌两项国内突破性疗法认定。当前全球暂无KRAS G12D靶向药获批,现有化疗、免疫方案获益有限,GFH375具备同类最佳潜力,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10